QualityStocksNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Update on Company Objectives and Programs
InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development and manufacturing of rare cannabinoids and cannabinoid analogs, is reporting an update on the company’s research/development and commercial activities. According to the update, the company is working to complete enrollment in a phase 2 clinical program in epidermolysis bullosa (‘EB’) by the end of 2023, to advance its R&D efforts on a preclinical drug candidate in ocular disease and to investigate the potential of proprietary cannabinoid analogs in targeting specific diseases. The update included an observation that market demand for INM’s BayMedica naturally occurring cannabinoids is not progressing as anticipated,…